Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 3
Submit an article Journal homepage
191
Views
29
CrossRef citations to date
0
Altmetric
Drug Evaluation

G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

A D Gilliam University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen’s Medical Centre, University Hospital, Nottingham, NG7 2UH, UK. [email protected]
&
S A Watson University of Nottingham, Division of Preclinical Oncology, D Floor, West Block, Queen’s Medical Centre, University Hospital, Nottingham, NG7 2UH, UK. [email protected]
Pages 397-404 | Published online: 19 Feb 2007

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Chizuru Ogi & Atsushi Aruga. (2013) Immunological monitoring of anticancer vaccines in clinical trials. OncoImmunology 2:8.
Read now
Chizuru Ogi & Atsushi Aruga. (2013) Clinical evaluation of therapeutic cancer vaccines. Human Vaccines & Immunotherapeutics 9:5, pages 1049-1057.
Read now

Articles from other publishers (27)

Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Nikolaos-Iasonas Kouris, George Papaxoinis, Michalis V Karamouzis, Anna Koumarianou & Dimitrios Schizas. (2022) Immunotherapy for gastric cancer: a 2021 update. Immunotherapy 14:1, pages 41-64.
Crossref
Akira Yoneda, Tamotsu Kuroki & Susumu Eguchi. (2021) Immunotherapeutic advances in gastric cancer. Surgery Today 51:11, pages 1727-1735.
Crossref
Michele Ghidini, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco & Shelize Khakoo. (2021) How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. Journal of Clinical Medicine 10:7, pages 1412.
Crossref
Luhong Yang, Yanxia Wang & Huafeng Wang. (2019) Use of immunotherapy in the treatment of gastric cancer (Review). Oncology Letters.
Crossref
Adrian Bot, Elliot M. Berinstein & Neil L. Berinstein. 2018. Plotkin's Vaccines. Plotkin's Vaccines 161 184.e6 .
Toru Mizuguchi, Toshihiko Torigoe, Fukino Satomi, Hiroaki Shima, Goro Kutomi, Shigenori Ota, Masayuki Ishii, Hiroshi Hayashi, Sumiyo Asakura, Yoshihiko Hirohashi, Makoto Meguro, Yasutoshi Kimura, Toshihiko Nishidate, Kenji Okita, Masaho Ishino, Atsushi Miyamoto, Masamitsu Hatakenaka, Noriyuki Sato & Koichi Hirata. (2015) Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?. Surgery Today 46:2, pages 139-148.
Crossref
Chizuru Ogi & Atsushi Aruga. (2015) Approaches to improve development methods for therapeutic cancer vaccines. Immunology Letters 164:2, pages 100-108.
Crossref
Jill P. Smith, Timothy K. Cooper, Christopher O. McGovern, Evan L. Gilius, Qing Zhong, Jiangang Liao, Alfredo A. Molinolo, J. Silvio Gutkind & Gail L. Matters. (2014) Cholecystokinin Receptor Antagonist Halts Progression of Pancreatic Cancer Precursor Lesions and Fibrosis in Mice. Pancreas 43:7, pages 1050-1059.
Crossref
Darshil T. Jhaveri, Lei Zheng & Elizabeth M. Jaffee. (2014) Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology 41:5, pages 559-575.
Crossref
Carlos Hernández, María Dolores Barrachina, Jesús Cosín-Roger, Dolores Ortiz-Masiá, Ángeles Álvarez, Liria Terrádez, María Jesús Nicolau, Rafael Alós, Juan Vicente Esplugues & Sara Calatayud. (2014) Progastrin Represses the Alternative Activation of Human Macrophages and Modulates Their Influence on Colon Cancer Epithelial Cells. PLoS ONE 9:6, pages e98458.
Crossref
Pelin Cinar & Margaret A. Tempero. (2012) Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer. The Cancer Journal 18:6, pages 653-664.
Crossref
Andrew D. Gilliam, Paul Broome, Eskender G. Topuzov, Avgust M. Garin, Istvan Pulay, Jane Humphreys, Anne Whitehead, Arjun Takhar, Brian J. Rowlands & Ian J. Beckingham. (2012) An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer. Pancreas 41:3, pages 374-379.
Crossref
Sarah Kraus, Victoria Lisiansky, Jeffrey Zweig, Elena Kapilevich & Nadir Arber. 2011. Inflammation, Lifestyle and Chronic Diseases. Inflammation, Lifestyle and Chronic Diseases.
Magda F. Morton, Terrance D. Barrett, Jamie Freedman, Lina Li, Michele C. Rizzolio, Clodagh E. Prendergast, Xiaodong Wu, Veronica Moreno, Jayashree Pyati, Katherine Figueroa, Laurence Cagnon, Guy Lagaud, Luc Ver Donck, Etienne Ghoos, Brett Allison, Michael H. Rabinowitz & Nigel P. Shankley. (2011) JNJ-26070109 [( R )4-Bromo- N -[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability . Journal of Pharmacology and Experimental Therapeutics 338:1, pages 328-336.
Crossref
Chiara Tieppo, Corrado Betterle, Daniela Basso, Claudia Mescoli, Massimo Rugge, Chiara Martini, Valerio Zorzetto, Gemma Maddalo, Nora Cazzagon, Donato Nitti & Fabio Farinati. (2011) Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. Cancer Immunology, Immunotherapy 60:7, pages 1057-1060.
Crossref
Magda Morton, Clodagh Prendergast & Terrance D. Barrett. (2011) Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends in Pharmacological Sciences 32:4, pages 201-205.
Crossref
Oneel Patel, Kathryn M. Marshall, Gianni Bramante, Graham S. Baldwin & Arthur Shulkes. (2010) The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway. Regulatory Peptides 165:2-3, pages 224-231.
Crossref
Peter Timmerman, Susana G. Shochat, Johan Desmet, Rodrigo Barderas, Jose Ignacio Casal, Rob H. Meloen & Danièle Altschuh. (2010) Binding of CDR-derived peptides is mechanistically different from that of high-affinity parental antibodies. Journal of Molecular Recognition 23:6, pages 559-568.
Crossref
Shahrad Taheri, Mohammad A. Ghatei & Stephen R. Bloom. 2010. Endocrinology. Endocrinology 2759 2773 .
Peter Timmerman, Rodrigo Barderas, Johan Desmet, Danièle Altschuh, Susana Shochat, Martine J. Hollestelle, Jo W.M. Höppener, Alberto Monasterio, J.Ignacio Casal & Rob H. Meloen. (2009) A Combinatorial Approach for the Design of Complementarity-determining Region-derived Peptidomimetics with in Vitro Anti-tumoral Activity. Journal of Biological Chemistry 284:49, pages 34126-34134.
Crossref
Ssucheng J. Hsu, Amita Patel, Paul D. Larsen, David J. Bohmann, Robert J. Bauer, Jeremy K. Ma, Linda Masat, Marina Roell, Susan J. Babuka, Rhonda K. Hansen, Mark White & Mary Haak-Frendscho. (2008) Development of XPA067.06, a potent high affinity human anti-gastrin monoclonal antibody. Biochemical Pharmacology 76:3, pages 340-352.
Crossref
Rodrigo BarderasJohan DesmetPeter Timmerman, Rob Meloen & J. Ignacio Casal. (2008) Affinity maturation of antibodies assisted by in silico modeling . Proceedings of the National Academy of Sciences 105:26, pages 9029-9034.
Crossref
Daniel Albo, Buckminster Farrow & David H. Berger. (2008) Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer. Surgical Oncology Clinics of North America 17:2, pages 357-376.
Crossref
Florian Lordick, Tobias Schulze & Dirk Jäger. (2008) The role of biologics in stomach cancer. Targeted Oncology 3:2, pages 71-79.
Crossref
Dan Laheru, Eric Lutz, James Burke, Barbara Biedrzycki, Sara Solt, Beth Onners, Irena Tartakovsky, John Nemunaitis, Dung Le, Elizabeth Sugar, Kristen Hege & Elizabeth Jaffee. (2008) Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research 14:5, pages 1455-1463.
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:1, pages 79-111.
Crossref
Malcolm J. MooreDavid GoldsteinJohn HammArie FigerJoel R. HechtSteven GallingerHeather J. AuPawel MurawaDavid WaldeRobert A. WolffDaniel CamposRobert LimKeyue DingGary ClarkTheodora Voskoglou-NomikosMieke PtasynskiWendy Parulekar. (2007) Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25:15, pages 1960-1966.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.